Recognizes Brain Derived Neurotrophic Factor (BDNF). By dot blot, less than 0.1% cross-reactivity against mouse NGF, recombinant human NT3 or neurotrophin 4.
A 10 amino acid peptide corresponding to the amino-terminal of mouse Brain Derived Neurotrophic Factor (BDNF) coupled to ovalbumin. The sequence is H2N-HSDPARRGEL-COOH.
Anti-Brain Derived Neurotrophic Factor Antibody is an antibody against Brain Derived Neurotrophic Factor for use in ELISA, IH & WB.
Research Sub Category
Immunohistochemistry: 1-10 μg/mL (see suggested protocol).
Immunoblotting: 1-10 μg/mL. BDNF is not easily extracted in standard buffers. Dissected tissues should be homogenized in 10 volumes of 100mM phosphate buffer containing 1mM EDTA, 2M guanidine hydrochloride (pH7.2), and three protease inhibitors, 10mM N-ethylmaleimide, 0.36mM pepstatin, and 1mM PMSF. Homogenates are then sonicated and centrifuged at 46K x g for 30 minutes at 4°C. BDNF migrates as 18 kDa, with a homodimer at ~27-30 kDa.
ELISA (one-site): 1-10 μg/mL
Optimal working dilutions must be determined by end user.
18 kDa (monomer) and 27-30 kDa (homodimer)
Protein A Purified immunoglobulin fraction lyophilized from PBS, with no preservatives. Reconstitute with 500 μL of sterile distilled water (1 mg/mL).
Protein A Purfied
Maintain at -20 to -70°C in undiluted aliquots for up to 12 months. Avoid repeated freeze/thaw cycles. Glycerol (1:1) can be added for additional stability.
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.